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Abstract
Purpose of review Tight junctions (TJs) are specialized
differentiations of epithelial and endothelial cell mem-
branes. TJs play an important role in the adhesion of cells
and their interaction with each other. Most cancers origi-
nate from epithelial cells. Thus, it is of significance to
examine the role of TJs in the tumor microenvironment
(TME) and how they affect cancer metastasis.
Recent findings In epithelium-derived cancers, intactness
of the primary tumor mass is influenced by intercellular
structures as well as cell-to-cell adhesion. Irregularities of
these factors may lead to tumor dissociation and subse-
quent metastasis. Low expression of TJs is observed among
highly metastatic cancer cells.
Summary In this review, we summarized findings from
current literature in consideration of the role of TJs in
relation to the TME and cancer. Deeper understanding of
the mechanisms leading to TJ dysregulation is needed to
facilitate the design and conceptualization of new and
better therapeutic strategies for cancer.
Keywords Tight junctions  Intercellular permeability 
Tumor microenvironment  Metastasis  Cancer
Introduction
Since epithelial cells line hollow organs, they are prone to
damage and are much exposed to carcinogens in the
environment. For this reason, they demand high renewal
rate. Due to their vulnerability, about 90 % of human
cancers originate from the epithelial tissues [1•].
Constant remodeling of cell-to-cell contacts takes place
for renewal and replacement of old or damaged cells. In
addition, this process helps to incorporate newly differen-
tiated cells without compromising the integrity of the
barrier [2]. In epithelium-derived cancers, intactness of the
primary tumor mass is influenced by intercellular structures
as well as cell-to-cell adhesion [3]. These factors should be
maintained since irregularities may lead to tumor dissoci-
ation and subsequent metastasis [4]. Tight junctions (TJs)
are among those that preserve cell adhesiveness in this
tumor mass. Therefore, alterations in the TJs present could
result to split of the tumor mass [5]. In addition, TJs also
suppress cell proliferation [6].
Owing to these facts, research has focused greatly in
drawing the link between TJs and the tumor microenvi-
ronment (TME). In this review, we surveyed current lit-
erature in consideration of the role of TJs in relation to the
TME and cancer.
Characteristics of Tight Junctions
Tight junctions (TJs) are specialized differentiations of
epithelial cell membranes [5]. They form a continuous
intercellular barrier between epithelial cells and separate
tissue spaces which regulate selective transport across the
epithelium [7•].
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TJs serve various functions. Foremost, they seal inter-
cellular spaces and separate the apical and basolateral fluid
compartments of epithelia and endothelia. They regulate
epithelial and endothelial cell permeability and act as
points of contact between the plasma membranes of
neighboring cells, occluding the extracellular space. They
also act as cell-to-cell adhesion molecules. They play a role
in cell adhesion and paracellular barrier functions and form
an intercellular barrier and an intramembrane diffusion
fence [5]. The diffusion of solutes is regulated by TJs
through size and charge selectivity and differs depending
on epithelial cell type. TJs are impermeable to most
macromolecules but are permeable to inorganic ions. As
such, TJs, together with adherens junctions and desmo-
somes, maintain the integrity of the epithelial cell layer and
protect multicellular organisms from the external envi-
ronment [5]. In addition, they play a role in cell polarity,
differentiation, growth and proliferation through their
involvement in cell signaling processes. They are sug-
gested to be involved in the regulation of cell proliferation
by controlling epithelial cell microenvironment [8]. Due to
this, they are able to suppress malignant phenotype of cells
during tumorigenesis. Furthermore, they function as cell
migration barrier. Their functions are shown to be regu-
lated by phosphorylation. A link between barrier disruption
due to TJ dysfunction and disease has long been estab-
lished [9].
The main cause of lethality among cancer patients is
metastasis [10]. Metastasis takes place with various pre-
requisites. Primarily, cancer cells need to be able to sur-
mount the barriers, mostly epithelial and endothelial tissues
consisting of cells bound together by tight junctions (TJs).
Dissociated cells provide easy access to metastasizing
cancer cells. Therefore, the intactness of TJs helps prevent
cell dissociation [11, 12].
Tight Junctional Components
Transmembrane proteins occludin, claudins, junctional
adhesion molecules (JAMs), and tricellulin as well as
intracellular scaffold proteins like zonula occludens (ZO)




The first discovered molecular component of the TJs is
occludin [13]. Although it was first suggested to form the
structural unit of the TJs, it has later been found out that
embryonic stem cells lacking occludin are still capable of
forming TJ structures which shows that occludin is not
indispensable for TJ structural assembly. To demonstrate
this, occludin null mice were born without any signs of
abnormal phenotype but later showed growth retardation.
The TJs appear morphologically unaltered but histological
abnormalities were observed in several tissues [14]. In
addition, occludin knock-out mice manifest atrophic gas-
tritis, testicular atrophy, male infertility, salivary gland
dysfunction, osteoporosis, and brain calcifications [14, 15].
Apical-basal polarity is used to sense cell–cell contacts
on epithelial surfaces. It has been observed that hippo
pathway elements co-localize with occludin, creating a
possible sensor system in pancreatic epithelial cells which
may regulate their proliferation [16•]. It has been reported
that epigenetic silencing of occludin could promote
tumorigenic and metastatic properties of cancer cells [17].
For example, occludin was shown to inhibit Raf-1 signal-
ing which induces tumor growth [18]. A low level of
occludin expression results to an increased progression and
metastatic potential in breast, ovarian, endometrial, and
liver carcinoma [19–22]. The increased metastatic poten-
tial, however, might not be due to occludin downregulation
but the activation of epithelial to mesenchymal transition
(EMT) which leads to downregulation of adhesion-asso-
ciated proteins [23].
Claudins
Of the various proteins classified as TJs, the claudin family
made up of transmembrane proteins appears to be of major
significance for TJ selectivity. Expression of many types of
claudins is altered in cancer cells [5]. The expression of
one particular claudin may be upregulated or downregu-
lated depending on the type of cancer. Among the various
members of the claudin family, claudin-1, -3, -4, and -7 are
among the most frequently dysregulated both at the tran-
scriptional and post-transcriptional levels [24]. Physiologic
plasticity of the TJ involves claudin switching which is the
adaptability of claudin expression and gene-specific
retention in the TJ [25•].
Claudins are found to be involved in tumor progression
and play a role in epithelial to mesenchymal transition. The
expression pattern of claudins influences tumor behavior in
various types of epithelial neoplasia. For example,
decreased expression of claudin-1, -2, and -7 coincides
with more intrusive breast carcinoma [26–29]. Meanwhile,
overexpression of claudin-3 and -4 is found in several
neoplasias such as in ovarian, breast, pancreatic, and
prostate cancers [24]. Also, in order to clarify its role in
tumor progression, the role of claudin-7 in esophageal
squamous cell carcinoma was analyzed. Results proposed
that the reduced expression of claudin-7 could lead to
tumor progression and subsequent metastatic events [30].
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Junctional Adhesion Molecules
Junctional adhesion molecules (JAMs) are located in cell-
to-cell contacts such as tight junctions. They are expressed
by leukocytes and platelets as well as by epithelial and
endothelial cells [31]. They regulate cell interactions in the
immune system and tight junction formation in epithelial
and endothelial cells during the acquisition of cell polarity
[32]. JAMs are involved in the EMT, a process that plays a
vital role in the invasiveness and metastasis of various
cancers. It has been shown that JAM-A upregulation could
induce EMT and when JAM-A expression is silenced,
EMT is reversed [33•].
Plaque Proteins
Zonula Occludens
Zonula occludens (ZO) are scaffold-forming intracellular
plaque proteins located between the transmembrane pro-
teins and the actin cytoskeleton [34]. They regulate the
assembly of cellular junctions. They bind actin, occludin,
and claudins [35].
Several ZO are involved in cell proliferation. For
instance, ZO-1 is demonstrated to interact with so-called
ZO-1-associated nucleic acid binding (ZONAB) proteins, a
Y-box transcription factor. This implies that ZO-1 is
involved in gene expression regulation, cell proliferation,
and morphogenesis of epithelial tissue [36].
Decreased expression of ZO-1 was shown to correlate
with increased invasiveness in breast, colorectal, and
digestive tract cancers [37]. It is also found to be involved
in tumor invasion-associated EMT implicating its role in
tumor growth process [38].
Tumor Microenvironment
The tumor microenvironment (TME) is composed of all the
normal cells, blood vessels, signaling molecules, and
extracellular matrix (ECM) surrounding the tumor cells. It
is made up of malignant and nontransformed cells that
interact with each other such as endothelial cells, pericytes,
fibroblasts, adipocytes, and also contains cells of the
immune system, the tumor vasculature, and lymphatics
(Fig. 1) [39•].
The TME has the ability to influence tissue function as
well as the development of malignancies [40]. The
interaction as well as the penetration of both the
endothelium and mesothelium by a tumor cell is a sig-
nificant step for tumor metastasis. In order for carcinoma
to invade, tumor cells need to be able to degrade the
underlying basement membrane as well as the
extracellular matrix (ECM) as a first step. The breakdown
could then lead to invasion of neighboring tissue par-
enchyma [41]. However, since the TME has ways by
which to maintain its normal conditions, this could only
be possible once the TME is altered. In this case, deviant
immune responses and altered homeostasis facilitate and
modulate tumorigenesis. For instance, when the tumor
acquires the capacity to bypass the means by which the
TME signals it to normalcy, intercellular interactions are
disrupted, forcing the TME to adapt to the growing tumor
[42•].
Cancer cells are not the only ones responsible for the
manifestation of disease. Instead, normal cell types both
resident and recruited to the TME contribute to the per-
sistence of cancer and cancer-related symptoms. For
instance, alterations in both tumor and endothelial cells are
essential for cancer cells to grow and metastasize. The
dysregulation of significant TJ proteins leads to the loss of
cell-to-cell association, cell contact inhibition that results
to uncontrolled growth, and loss of adhesion to the base-
ment as well as its degradation [43].
Low expression of TJs is observed among highly
metastatic cancer cells. On the other hand, weakly
metastatic tumor cells demonstrate increased TJ expres-
sion. Control of cellular proliferation involves various TJ-
associated proteins such as transmembrane, adaptor and
signaling proteins as well as transcription factors. When
the expression levels of these proteins are changed,
intercellular permeability is increased, polarity and con-
tact inhibition are lost and expression of growth-stimu-
latory genes in the nucleus increases. According to
research conducted on human tumors, there is a correla-
tion of the loss of functional TJs in cancer progression
and metastasis. In addition, it has also been shown that
some proteins associated with TJs suppress tumors and
regulate signal transduction which suggests the partici-
pation of TJ disruption in early carcinogenesis. It has
been observed that mutant mice that lack specific TJ
proteins develop hyperproliferative disorders [44]. The
location of epithelial cells allows their direct exposure to
the external environment making them prone to injury or
attack by toxins, microbes, and viruses. Damage in the
epithelial cells brings about loss of TJ integrity. This
becomes a cue for the cells to launch a repair program
involving cellular proliferative and migratory activities in
the damaged area. This is accompanied by TJ reassembly
in order to reform the epithelial layer. The loss of
adherence between epithelial cells during the process of
EMT allows them to become more motile and acquire
mesenchymal characteristics. Studies show that this
mechanism relates to a functional loss of E-cadherin [45].
Other events associated with EMT are loss of polarity
which takes place together with the loss of TJs [46].
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Tight Junctions in Different Tumorigenic Tissues
Tight junctions (TJs) are important in the regulation of
selective transport across the epithelium [7•]. For this
reason, their involvement in cell proliferation through
control of the epithelial cell microenvironment is impli-
cated [8]. They are thus suggested to affect metastasis of
tumorigenic cells. Expression of TJ-associated proteins is
shown to be dysregulated in various tumorigenic tissues
(Table 1).
Glioma and Glioblastoma
Gliomas are the most frequent tumors of the central ner-
vous system. They are associated with a poor prognosis and
high lethality. The blood–brain barrier (BBB) restricts the
delivery of therapeutics into the brain making most of the
systemically administered drugs ineffective in the brain
tumor treatment. Progression of glioma leads to structural
changes in endothelial cells of the BBB resulting in
enhanced permeability and brain edema [47]. Damaged
cerebrovascular endothelial cells cEND cultured in the
presence or absence of astrocytic factors, for example,
induced mRNA expression of inflammatory markers, alter
calcium ion levels and decreased tight junction proteins
claudin-5 and occludin expression [48]. Severe cerebral
edema is observed in most patients with glioma and it is a
main cause of mortality in glioma patients. Vasogenic
edema is caused by the disturbance of the BBB either by
the destruction of TJs or by the increase of endothelial
fenestrations and pinocytosis [49].
Glucocorticoids (GCs) are the most common molecules
used to treat tumor-associated cerebral edema [50]. GCs
regulate the BBB and target occludin, claudins and VE-
cadherin. Transactivation of certain target genes leads to
improved barrier properties of endothelial cells [51]. For
instance, at the cellular level, GCs have been shown to
strengthen the BBB properties by increasing the
Fig. 1 The tumor microenvironment (TME) and tight junctions
(TJs). The TME is composed of normal cells, blood vessels, signaling
molecules, and extracellular matrix (ECM) surrounding the tumor
cells. Both malignant and nontransformed cells interacting with each
other are present. Vital to this interaction are the TJs which regulate
selective transport across the cells
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transendothelial electrical resistance (TEER) of endothelial
monolayer and decreasing the paracellular permeability for
small and large molecules [52, 53]. TJs proteins occludin,
claudin-5, and ZO-1 have been identified as GC targets at
the BBB [52–56]. GC treatment leads to direct binding of
glucocorticoid receptor to glucocorticoid response ele-
ments in the occludin promoter or to activation and binding
of other transcription factors such as p54 [57, 58]. GC-
mediated claudin-5 increase was observed in brain
endothelial cells from different species and the induction of
claudin-5 was observed at the promoter, mRNA, and pro-
tein levels [53, 54, 58]. In addition, induction of other
BBB-associated claudins, claudin-1 and -12, was observed
in brain endothelial cells after GC treatment [59, 60]. VE-
cadherin, a component of adherens junctions, plays a role
in the formation and regulation of TJs and is also induced
by GC-treatment [61].
Glioma cells express high amounts of vascular
endothelial growth factor (VEGF). VEGF is induced by
hypoxia, promotes angiogenesis and increases BBB per-
meability. Increased levels of VEGF lead to down-regu-
lation of TJ proteins claudin-5 and occludin [62]. GCs also
modulate the expression of VEGF in brain tumor cells and
in brain endothelial cells contributing in this way to the
stabilization of the BBB [63]. Downregulation of claudin-1
and claudin-5 has been detected in human glioma and has
been associated with tumor progression [64, 65]. However,
the BBB in peripheral glioma remains essentially intact and
this is one of the reasons for the poor treatment efficacy of
this tumor [66].
Cutaneous Squamous Carcinoma
TJs in epidermis form a barrier to prevent diffusion of
molecules from and into the body. Claudin-1 knock-out
mice showed fetal dehydration from skin due to impaired
barrier function in the epidermis [67]. During the pro-
gression of skin tumorigenesis, changes in the expression
and distribution pattern of TJ-proteins have been observed.
Human cutaneous squamous carcinoma (SCC), its precur-
sor tumors and sun-exposed skin models showed broader
localization of ZO-1 and claudin-4 as well as downregu-
lation of claudin-1 in deeper epidermal layers at the TJs in
comparison to healthy skin [68–70]. In addition, SCC
showed complete loss of occludin at the TJ. This feature
seems to be common for different types of tumors.
Table 1 Regulation of tight junctional (TJ) proteins expression in various tumorigenic tissues
Tumor type Tight junctions References Tight junctions References
downregulated upregulated
Mammary gland adenocarcinoma Claudin 1 [63, 72•] Claudin 3 [24, 29, 75•]
Claudin 2 [27] Claudin 4 [24, 29]
Claudin 3 [72•]
Claudin 4 [72•]
Claudin 7 [28, 29, 73, 74]
Claudin 12 [72•]
ZO-1 [70, 76, 77, 78]
ZO-2 [70, 76, 77, 78]
Glioma/Glioblastoma Claudin 1 [64, 65]
Claudin 5 [64, 65]




Hepatocellular carcinoma Claudin 1 [81]
Pulmonary carcinoma Claudin 6 [94]
Prostatic carcinoma Claudin 3 [24]
Claudin 4 [24]
Cutaneous squamous carcinoma Claudin 1 [68, 69] Claudin 2 [68]
Claudin 4 [69, 70]
Occludin [69]
ZO-1 [7•, 69]
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Occludin downregulation is associated with decreased
epithelial adhesion and susceptibility to apoptosis [69].
Claudin-2 upregulation accompanied by claudin-1 down-
regulation was associated with tumor progression [68].
Mammary Gland Adenocarcinoma
Cell-to-cell contacts in the epithelium are not just static
points that hold the cells together since they consistently
undergo remodeling and incorporation of newly differen-
tiated cells. Although this does not lead to loss of barrier
function, alterations in TJs could impact breast cancer
progression due to modified cell polarity, cell fate, and cell
migration. The major characteristic of cancer is abnormal
proliferation. However, progression of cancer is not only
determined by rapid proliferation in tumor cells. It is also
due to other factors such as apoptosis resistance as well as
the ability to bypass senescence pathways. In addition,
individual TJ proteins may also play a role in modulating
breast cancer progression.
Impairment of functional control over polarity and cell
fate determination, or cell motility characteristics, may
result from alterations in the TJ complex at the onset of
breast cancer. Dysregulation of these cellular processes
could lead to breast cancer progression and metastasis. The
differentiation of the mammary gland is significant in the
reduction of the risk reduction for breast cancer. In one
study, a role for the estrogen receptor b (ERb-/-) in the
organization and adhesion of epithelial cells as well as for
differentiated tissue morphology was suggested. Findings
implicated that by facilitating terminal differentiation of
the mammary gland ERb could contribute to the risk
reduction for breast cancer [71].
In another study, functional regions of occludin in human
tissues and breast cancer cell lines were amplified. It has
been observed that tumor tissues have truncated or variant
signals of occludin. Moreover, expression of occludin in
the human breast cancer cell lines tested also varied. This
demonstrates the significance of occludin in TJ integrity
maintenance in breast tissues [22].
One study showed a link between the expression of
interleukin (IL)-18, reported to have a pro-tumor effect in
various cancers, and claudins in breast cancer migration.
This study showed that exogenous IL-18 could enhance
breast cancer cell migration and inhibit the expression of
claudin-1, 3, 4, and 12 in human breast cancer cell lineMCF-
7. Upon knocking down these claudins, all except claudin-1
increased breast cancer cell migration with claudin-12 gen-
erating the most effects. The results suggest that IL-18 is
important for the induction of breast cancer cell migration by
down-regulating claudin-12 and activating the p38 mitogen-
activated protein kinase (MAPK) pathway [72•]. Another
study showed that expression of claudin-7 is lower in
invasive ductal carcinomas of the breast compared to normal
breast epithelium [29]. In addition, reduced expression of
claudin-7 corresponds to a higher tumor grade as well as
metastatic disease [73]. Using immunohistochemistry and
tissue microarray, it was observed that claudin-7 is strongly
expressed in normal luminal epithelial cells of the breast
lobule compared to ductal carcinoma and invasive breast
carcinoma.Claudin-7was significantly lower or absent in the
carcinomas [74]. Still in another study conducted using two
breast cancer cell lines of metastatic origin (MCF-7 and
MDA-MB-415), a marked overexpression of claudin-3
protein was shown. When protein levels of claudin-3 were
suppressed, the rate of cellular motility decreased. These
results could indicate that claudin-3 overexpression may
play an important role in the disruption of TJ integrity
leading to enhanced cell motility which is a key determinant
of tumor progression [75•].
Meanwhile, lowZO-1 and ZO-2 expressionwere observed
to correlate with poor prognosis in breast cancer [70, 71,
76–78].
Prostatic Carcinoma
Like in many organs and tissues such as the brain, the
enteric epithelium or the testis where TJs abound due to the
presence of a barrier where they help to regulate barrier
function, it has been shown that TJs also exist in prostate
tissue due to the blood-prostate barrier [72•]. In one study,
the effect of hepatocyte growth factor (HGF) on TJ func-
tion in human prostate epithelial, prostate stem cell-like
and prostate cancer cell lines was evaluated. It has been
demonstrated that HGF could impact the metastasis of
prostate cancer. During this process, TJs play a vital role
and they are found to be regulated by HGF. TJ function
regulation by HGF was found to be dependent on cell
tumorigenicity [79•]. In another study, the overexpression
of claudins is implicated in the invasive potential of human
prostate cancer. The effects of flavonoids have been studied
and it was observed that they subdue claudin expression
which leads to suppression of cancer migration and inva-
sion [80].
Hepatocellular Carcinoma
Loss of TJs in the liver has been associated with malignant
transformation. Nonetheless, a growing body of evidence
reveals the upregulation of TJ protein expression in cancer
tissue and their role in cell invasion and metastatic pro-
gression. In hepatocellular carcinoma (HCC), overexpres-
sion of claudin-1 led to increased expression of
transcription factors regulating epithelial-mesenchymal
transition (EMT) of human liver cells [81]. However,
another study showed correlation of claudin-1
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downregulation and a poor prognosis in HCC. Claudin-7
mRNA overexpression was also detected in HCC. In this
case, overexpression of claudin-7 correlated with a better
prognosis among patients [82]. Downregulation of claudin-
5 expression in sinusoidal endothelial cells of HCC patients
was correlated with a poor prognosis [83].
Gastric/Colorectal Adenocarcinoma
Claudins are vital for the absorption of nutrients in the small
intestine [84]. In the same way, they are vital in cell prolif-
eration and transformation during cancer. For instance, in
colon cancer, claudin-1 was shown to promote transforma-
tion as well as metastatic behavior [85]. Expression of
claudin-1, -4, and -7 was found to decrease in colorectal
cancer. This implies critical effects on cell proliferation,
motility, invasion, and immune response against the tumor
[86•]. One study did an analysis of the allele frequencies on
three common single nucleotide polymorphisms (SNPs) in
the genes for claudin-1 and 7 in colon cancer patients. It was
observed that polymorphisms in both claudins investigated
are related to differentiation and tumor state in colon cancer
[87•]. On the other hand, deficiency in claudin-15 results to
megaintestine and a decreased paracellular ion permeability
of the intestinal epithelium. Nonetheless, no tumorigenesis
was detected among those exhibiting the phenotype [8].
Also, in colorectal cancer, it has been demonstrated that
resveratrol, a naturally occurring polyphenol, upregulates
intercellular junctions such as desmosomes, gap- and tight
junctions (claudin-2), and adhesionmolecules (E-cadherin).
On the other hand, it downregulates the NF-jB pathway.
These processes lead to inhibition of the EMT phenotype
[88]. In another study, CITED4, a transcriptional cofactor
deregulated in colorectal cancer, was knocked down via
shRNA-mediation in the colorectal cancer cell line SW480.
Changes in proliferation, apoptosis/cell cycle, migration,
invasion, colony formation, and adhesion were analyzed.
Decreased cellular proliferation and modulation of actin-
associated adherens junctions/TJs expression have been
observed [89].
Meanwhile, the function of junctional adhesion mole-
cules (JAMs) which comprise the integral parts of TJs in the
gastric epithelium and in gastric cancer cell proliferation,
invasion, and apoptosis was investigated. It has been shown
that JAM-A promotes the proliferation but inhibits apoptosis
of gastric cancer [90]. On the other hand, decreased ZO-1
expression was noted in the human digestive tract.
Pulmonary Carcinoma
The expression of TJ proteins such as claudins in different
lung tumors varies. For instance, occludin was found in
adenocarcinomas but not in squamous cell carcinomas,
small or large cell carcinomas [91]. Meanwhile, claudins
show variable patterns of expression in tumor cells.
Squamous cell carcinomas express claudin 1 but not
claudin 5 while adenocarcinomas express claudin 5 but not
claudin 1 [20]. Epithelial metastases of lung tumors
showed a 50–70 % expression of claudins 1, 2, 3, 4, and 5
and a 90 % expression of claudin 7 [92]. TJ proteins are
usually overexpressed in lung tumors. Besides TJ protein
overexpression, matrix metalloproteinases are also
increased which leads to spread of the tumor [93]. On the
other hand, immunohistochemical study of tissue from
patients with nonsmall cell lung cancer revealed low
claudin-6 expression indicative of a worse prognosis [94].
Nonetheless, permeability of pulmonary epithelium can be
governed by various factors. For example, in using human
alveolar epithelium cell line H441, it has been shown that
soluble factors obtained from human lung endothelial cell
line HPMEC-ST1.6R could influence the barrier properties
of the former [95]. Thus, in the TME where there is
interplay of different cell types, the possible effects that the
different interactions among these cells bring about need to
be further explored.
Cytokines, Tight Junctions, and the Tumor
Microenvironment
Dysfunction in the TME as well as the epithelium can be
crucial for carcinogenesis [96]. It is suggested that cancer
cases are triggered by mutation and inflammation, although
most cases have unknown origin [97]. Chronic inflamma-
tion could lead to cellular events that promote cell trans-
formation resulting to cancer formation. Inflammation
activates cytokine production within the TME [98]. There
is greater oxidative stress in the microenvironment sur-
rounding inflammation compared to normal. Inflammation
leads to expression of cytokines which in turn activates the
inflammatory cascade [97]. Moreover, cytokines contribute
to the promotion of cell tumor proliferation as well as
apoptosis inhibition and anti-tumor immunity suppression.
When epithelium surrounding the stroma is altered, it also
alters the stroma along with the mediators leading to TME
formation [99]. In the same manner, when TJs within the
TME are disrupted, cytokine-mediated perturbation of TJs
occurs which in turn leads to increased paracellular per-
meability [100] and promotes TJ remodeling [101].
Conclusions
The tumor microenvironment (TME) engages a complex
interaction among the component cells that comprise it.
Communication and cross-talk in the TME are maintained
Curr Pathobiol Rep (2016) 4:135–145 141
123
by the tight junctions (TJs). Dysregulation of TJs at the
TME could affect cell permeability which could influence
tumor metastasis. Hereof, deeper understanding of the
mechanisms surrounding TJ dysregulation is needed to
facilitate the design and conceptualization of new and
better therapeutic strategies for cancer.
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